A clinical study evaluating dendritic and cytokine-induced killer cells combined with concurrent radiochemotherapy for stage IIIB non-small cell lung cancer

Genetics and Molecular Research

Volumn 14, Issue 3, 2015, Pages 10228-10235

  Zhu, X P ^a,d   Xu, Y H ^b   Zhou, J ^c   Pan, X F ^c  

^a YANGTZE UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c JINGZHOU CENTRAL HOSPITAL   (China)

^d Internal Medicine Oncology   (China)

Author keywords

Concurrent chemoradiotherapy; Cytokine induced killer cells; Dendritic cells; Non small cell lung cancer

Indexed keywords

CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; CYTOKERATIN 19 FRAGMENT; DOCETAXEL; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; DENDRITIC CELL; ESOPHAGITIS; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; HUMAN CELL; KARNOFSKY PERFORMANCE STATUS; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; QUALITY OF LIFE; RADIATION DOSE; RADIATION PNEUMONIA; SURVIVAL RATE; T LYMPHOCYTE SUBPOPULATION; TREATMENT RESPONSE; ADVERSE EFFECTS; CARCINOMA, NON-SMALL-CELL LUNG; IMMUNOLOGY; LUNG NEOPLASMS; LYMPHOCYTE SUBPOPULATION; METABOLISM; MORTALITY; PATHOLOGY; TIME FACTOR; TREATMENT OUTCOME;

AGED; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; CYTOKINE-INDUCED KILLER CELLS; DENDRITIC CELLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KARNOFSKY PERFORMANCE STATUS; LUNG NEOPLASMS; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84940549066     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2015.August.28.6     Document Type: Article

References (14)

1. Bearz A, Minatel E, Abu Rumeileh I, Borsatti E, et al. (2013). Concurrent chemoradiotherapy with tomotherapy in locally advanced non-small cell lung cancer: a phase I, docetaxel dose-escalation study, with hypofractionated radiation regimen. BMC Cancer 13: 513.
2. Casal Rubio J, Fírvida-Pérez JL, Lázaro-Quintela M, Barón-Duarte FJ, et al. (2014). A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study. Cancer Chemother. Pharmacol. 73: 451-457.
3. Chang A (2011). Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 71: 3-10.
4. Hazelrigg MR, Hirsch JI and Merchant RE (2002). Distribution of adoptively transferred, tumor-sensitized lymphocytes in the glioma-bearing rat. J. Neurooncol. 60: 143-150.
5. Jiang J, Xu N, Wu C, Deng H, et al. (2006). Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. Anticancer Res. 26: 2237-2242.
6. Jiang J, Wu C and Lu B (2013). Cytokine-induced killer cells promote antitumor immunity. J. Transl. Med. 11: 83.
7. Mehrian M, Asemani D, Arabameri A, Pourgholaminejad A, et al. (2013). Modeling of tumor growth in dendritic cell-based immunotherapy using artificial neural networks. Comput. Biol. Chem. 29: 21-28.
8. Nicol AJ, Tazbirkova A, MacFarlane D, Nieda M, et al. (2012). Effect of cryopreservation, type of antigen and route of administration on in vivo migration of human monocyte-derived dendritic cells. J. Clin. Oncol. 30: el3128.
9. NSCLC Meta-Analyses Collaborative Group (2008). Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J. Clin. Oncol. 26: 4617-4625.
10. Pereira JR, Cheng R, Orlando M, Kim JH, et al. (2013). Elderly subset analysis of randomized phase III study comparing pemetrexed plus carboplatin with docetaxel plus carboplatin as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer. Drugs R D 13: 289-296.
11. Takayama K, Inoue K, Tokunaga S, Matsumoto T, et al. (2013). Phase II study of concurrent thoracic radiotherapy in combination with weekly paclitaxel plus carboplatin in locally advanced non-small cell lung cancer: LOGIK0401. Cancer Chemother. Pharmacol. 72: 1353-1359.
12. Tsuchida Y and Therasse P (2001). Response evaluation criteria in solid tumors (RECIST): new guidelines. Med. Pediatr. Oncol. 37: 1-3.
13. Yang LL, Ren BZ, Li H, Yu J, et al. (2013). Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. Cancer Immunol. Immunother. 62: 65-73.
14. Zhi X, Gao W, Han B, Yang Y, et al. (2013). VATS lobectomy facilitates the delivery of adjuvant docetaxel-carboplatin chemotherapy in patients with non-small cell lung cancer. J. Thorac. Dis. 5: 578-584.